We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · December 09, 2020

Risk of Hepatocellular Carcinoma Development in Patients With Treated Chronic Hepatitis B– Related Cirrhosis

Alimentary Pharmacology & Therapeutics


Additional Info

Alimentary Pharmacology & Therapeutics
Five-Year Comparative Risk of Hepatocellular Carcinoma Development Under Entecavir or Tenofovir Treatment-Naïve Patients With Chronic Hepatitis B-Related Compensated Cirrhosis in Taiwan
Aliment. Pharmacol. Ther. 2020 Dec 01;52(11-12)1695-1706, TH Hu, S Yueh-Hsia Chiu, PL Tseng, CH Chen, SN Lu, JH Wang, CH Hung, KM Kee, MT Lin, KC Chang, MC Lin, RN Chien

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading